<SEC-DOCUMENT>0001193125-24-060883.txt : 20240306
<SEC-HEADER>0001193125-24-060883.hdr.sgml : 20240306
<ACCEPTANCE-DATETIME>20240306172553
ACCESSION NUMBER:		0001193125-24-060883
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20240305
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240306
DATE AS OF CHANGE:		20240306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Akero Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001744659
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38944
		FILM NUMBER:		24727154

	BUSINESS ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
		BUSINESS PHONE:		650-487-6488

	MAIL ADDRESS:	
		STREET 1:		601 GATEWAY BOULEVARD, SUITE 350
		CITY:			SOUTH SAN FRANCISCO
		STATE:			CA
		ZIP:			94080
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d808358d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:akro="http://www.akerotx.com/20240305" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-278">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-03-05_to_2024-03-05">0001744659</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="akro-20240305.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-03-05_to_2024-03-05"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001744659</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-03-05</xbrli:startDate> <xbrli:endDate>2024-03-05</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-289">8-K</ix:nonNumeric></span></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-03-05_to_2024-03-05" format="ixt:datemonthdayyearen" id="ixv-290">March 5, 2024</ix:nonNumeric></p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-291">Akero Therapeutics, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-03-05_to_2024-03-05" format="ixt-sec:stateprovnameen" id="ixv-292">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-293">001-38944</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-294">81-5266573</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(I.R.S. Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr>
<tr style="font-size:1pt">
<td style="height:9.75pt" colspan="3"/>
<td style="height:9.75pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:bottom" colspan="3"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-295">601 Gateway Boulevard</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-296">Suite 350</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-297">South San Francisco</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-298">CA</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-299">94080</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top" colspan="3"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-300">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-301">487-6488</ix:nonNumeric></span></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-03-05_to_2024-03-05" format="ixt-sec:boolballotbox" id="ixv-302">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-03-05_to_2024-03-05" format="ixt-sec:boolballotbox" id="ixv-303">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to <span style="white-space:nowrap">Rule&#160;14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-03-05_to_2024-03-05" format="ixt-sec:boolballotbox" id="ixv-304">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to <span style="white-space:nowrap">Rule&#160;14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-03-05_to_2024-03-05" format="ixt-sec:boolballotbox" id="ixv-305">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to <span style="white-space:nowrap">Rule&#160;13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-306">Common Stock, par value $0.0001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-307">AKRO</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-03-05_to_2024-03-05" format="ixt-sec:exchnameen" id="ixv-308">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;&#160;230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 <span style="white-space:nowrap">(&#167;&#160;240.12b-2</span> of this chapter).</p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-03-05_to_2024-03-05" format="ixt-sec:boolballotbox" id="ixv-309">&#9744;</ix:nonNumeric></p> <p style="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;&#9744;</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March 5, 2024, Akero Therapeutics, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement (the &#8220;<span style="text-decoration:underline">Underwriting Agreement</span>&#8221;) with J.P. Morgan Securities LLC, Morgan Stanley&#160;&amp; Co. LLC, Jefferies LLC, and Evercore Group L.L.C. as representatives of the several underwriters named therein (the &#8220;<span style="text-decoration:underline">Underwriters</span>&#8221;) pursuant to which the Company agreed to issue and sell 11,000,000 shares of the Company&#8217;s common stock, par value $0.0001 per share (the &#8220;<span style="text-decoration:underline">Common Stock</span>&#8221;), to the Underwriters at a public offering price of $29.00 per share (the &#8220;<span style="text-decoration:underline">Offering</span>&#8221;). Under the terms of the Underwriting Agreement, the Company also granted the Underwriters an option exercisable for 30 days to purchase up to an additional 1,650,000 shares of Common Stock at the same price per share. The Offering is expected to close on or about March 8, 2024, subject to customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds to the Company from the Offering are expected to be approximately $299.4&#160;million after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company, or approximately $344.4&#160;million if the underwriters exercise their option to purchase additional shares from the Company in full. The Company intends to use the net proceeds from the Offering, together with its existing cash, cash equivalents and marketable securities and committed capital assuming the closing of the Offering, to continue to advance the clinical development of efruxifermin (&#8220;EFX&#8221;), including the Company&#8217;s ongoing Phase 2b HARMONY, Phase 3 SYNCHRONY Histology, and Phase 3 SYNCHRONY Real-World studies, manufacture of drug product, and the Company&#8217;s Phase 3 SYNCHRONY Outcomes study, with the remainder for working capital and other general corporate purposes. The Company may also use a portion of its net proceeds, together with its existing cash, cash equivalents and marketable securities and committed capital assuming the closing of the Offering, to develop, <span style="white-space:nowrap">co-develop,</span> acquire or invest in products, that are complementary to EFX to expand its pipeline. However, the Company currently does not have any agreements or commitments to complete any such transaction. The Company believes that the net proceeds from this offering, together with its cash, cash equivalents and marketable securities and committed capital assuming the closing of the Offering will be sufficient to fund its current operating plan into 2027. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Offering was made pursuant to the Company&#8217;s Registration Statement on Form <span style="white-space:nowrap">S-3ASR</span> (File <span style="white-space:nowrap">No.&#160;333-256229)</span> (the &#8220;Registration Statement&#8221;), which was previously filed with the Securities and Exchange Commission and automatically became effective on May&#160;18, 2021, and a related prospectus included in the Registration Statement, as supplemented by a preliminary prospectus supplement dated March&#160;4, 2024 and a final prospectus supplement dated March 5, 2024. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties and covenants of the Company and also provides for customary indemnification obligations of the Company and the Underwriters, including for liabilities under the&#160;Securities Act of 1933, as amended. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates and were solely for the benefit of the parties to such agreement. The foregoing summary of the Underwriting Agreement is qualified in its entirety by reference to the Underwriting Agreement, a copy of which is attached hereto as Exhibit 1.1 and incorporated herein by reference. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP, counsel to the Company, delivered an opinion as to legality of the issuance and sale of the Common Stock in the Offering, a copy of which is attached hereto as Exhibit 5.1 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Cautionary Note Regarding Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> and certain of the materials filed herewith contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the Offering, and expectations regarding our cash runway, use of capital, expenses and other future financial results. The words &#8220;may,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;estimate,&#8221; &#8220;seek,&#8221; &#8220;predict,&#8221; &#8220;future,&#8221; &#8220;project,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;target&#8221; and similar words or expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements, such as those related to the anticipated closing of the Offering, are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form <span style="white-space:nowrap">8-K</span> or the materials furnished or filed herewith, including, without limitation, uncertainties related to market conditions and the completion of the Offering on the anticipated terms or at all. These and other risks and uncertainties are described in greater detail in the section entitled &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form <span style="white-space:nowrap">10-K</span> for the year ended December&#160;31, 2023 and any subsequent filings with the Securities and Exchange Commission. In addition, any forward-looking statements represent the Company&#8217;s views only as of today and should not be relied upon as representing its views as of any subsequent date. The Company explicitly disclaims any obligation to update any forward-looking statements. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01.</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:3%"/>
<td style="width:94%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d808358dex11.htm">Underwriting Agreement, dated as of March&#160;5, 2024, by and between the Company, J.P. Morgan, Morgan Stanley, Jefferies, and Evercore, as representatives of the several underwriters named therein </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8199;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d808358dex51.htm">Opinion of Goodwin Procter LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d808358dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit 5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded with Inline XBRL document)</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:4%"/>

<td style="vertical-align:bottom"/>
<td style="width:3%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:45%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: March&#160;6, 2024</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3"><span style="font-weight:bold">AKERO THERAPEUTICS, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Cheng</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"/>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrew Cheng, M.D., Ph.D.</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">President and Chief Executive Officer</p></td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d808358dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Akero Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11,000,000 Shares of Common Stock, par value $0.0001 per share </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">March&nbsp;5, 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;several Underwriters listed </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8195;in Schedule 1 hereto
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Morgan Stanley&nbsp;&amp; Co. LLC
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1585 Broadway </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10036 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group L.L.C. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10055 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Akero Therapeutics, Inc.,
a Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the &#147;Underwriters&#148;), for whom you are acting as representatives (the &#147;Representatives&#148;), an
aggregate of 11,000,000 shares of common stock, par value $0.0001 per share (the &#147;Common Stock&#148;), of the Company (the &#147;Underwritten Shares&#148;) and, at the option of the Underwriters, up to an additional 1,650,000 shares of Common
Stock of the Company (the &#147;Option Shares&#148;). The Underwritten Shares and the Option Shares are herein referred to as the &#147;Shares&#148;. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the
Shares are referred to herein as the &#147;Stock&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms its agreement with the several Underwriters
concerning the purchase and sale of the Shares, as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Registration Statement</U>. The Company has prepared and filed with the
Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3ASR</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-256229),</FONT> including a prospectus, relating to the Shares. The Company meets the requirements for use of Form
<FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The proposed offering of the Shares </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
may be made pursuant to General Instruction 1.B.1 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> Such registration statement, as amended at the time it became effective, including the
information, if any, deemed pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of the registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as the &#147;Registration
Statement&#148;; and as used herein, the term &#147;Preliminary Prospectus&#148; means each prospectus included in such registration statement (and any amendments thereto) before effectiveness, any prospectus filed with the Commission pursuant to
Rule 424(a) under the Securities Act and the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule 430 Information, and the term &#147;Prospectus&#148; means the prospectus in the form first used (or made
available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Shares. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities
Act (the &#147;Rule 462 Registration Statement&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this
&#147;Agreement&#148;) to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form
<FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus, as the case may be, and any reference to &#147;amend&#148;,
&#147;amendment&#148; or &#147;supplement&#148; with respect to the Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Securities Exchange Act of
1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Exchange Act&#148;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings
given to such terms in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the Applicable Time (as defined below), the Company
had prepared the following information (collectively with the pricing information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): a Preliminary Prospectus dated March&nbsp;4, 2024 and each &#147;free-writing prospectus&#148; (as
defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 8:00 P.M., New York
City time, on March&nbsp;5, 2024. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase of the Shares by the Underwriters</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Company agrees to issue and sell the Underwritten Shares to the several Underwriters as provided in this Agreement, and
each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase at a price per share of $27.26 (the &#147;Purchase
Price&#148;) from the Company the respective number of Underwritten Shares set forth opposite such Underwriter&#146;s name in Schedule 1 hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, the Company agrees to issue and sell the Option Shares to the several Underwriters as provided in this Agreement, and the
Underwriters, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase, severally and not jointly, from the Company the Option Shares at the
Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable on the Underwritten Shares but not payable on the Option Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If any Option Shares are to be purchased, the number of Option Shares to be purchased by
each Underwriter shall be the number of Option Shares which bears the same ratio to the aggregate number of Option Shares being purchased as the number of Underwritten Shares set forth opposite the name of such Underwriter in Schedule 1 hereto (or
such number increased as set forth in Section&nbsp;10 hereof) bears to the aggregate number of Underwritten Shares being purchased from the Company by the several Underwriters, subject, however, to such adjustments to eliminate any fractional Shares
as the Representatives in their sole discretion shall make. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Underwriters may exercise the option to purchase Option Shares at any
time in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus, by written notice from the Representatives to the Company. Such notice shall set forth the aggregate number of Option Shares as to
which the option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor
later than the tenth (10<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) full business day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions of Section&nbsp;10
hereof). Any such notice shall be given at least two (2)&nbsp;business days prior to the date and time of delivery specified therein, provided that if such date and time of delivery are the same as the Closing Date, such notice may be given one
business day prior to such date and time of delivery. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Company understands that the Underwriters intend to make a
public offering of the Shares, and initially to offer the Shares on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Shares to or through any affiliate of an
Underwriter. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Payment for the Shares shall be made by wire transfer in immediately available funds to the account
specified by the Company to the Representatives in the case of the Underwritten Shares, at the offices of Cooley LLP, counsel for the Underwriters, at 3 Embarcadero Center, 20th Floor, San Francisco, CA 94111, at 10:00 A.M., New York City time, on
March&nbsp;8, 2024 or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing or, in the case of the Option Shares, on the date
and at the time and place specified by the Representatives in the written notice of the Underwriters&#146; election to purchase such Option Shares. The time and date of such payment for the Underwritten Shares is referred to herein as the
&#147;Closing Date&#148;, and each time and date for such payment for the Option Shares, if other than the Closing Date, is herein referred to as an &#147;Additional Closing Date&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Payment for the Shares to be purchased on the Closing Date or an Additional Closing Date, as the case may be, shall be made
against delivery to the Representatives for the respective accounts of the several Underwriters of the Shares to be purchased on such Closing Date or the Additional Closing Date, as the case may be, with any transfer taxes payable in connection with
the sale of such Shares duly paid by the Company. Delivery of the Shares shall be made through the facilities of The Depository Trust Company (&#147;DTC&#148;) unless the Representatives shall otherwise instruct. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) The Company acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the capacity
of an arm&#146;s length contractual counterparty to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an
agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The
Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor the other
Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to such
transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3. <U>Representations and Warranties of the Company</U>. The Company represents and warrants
to each Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Preliminary Prospectus.</I> No order preventing or suspending the use of any Preliminary
Prospectus has been issued by the Commission, and each Preliminary Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the applicable requirements of the Securities Act, and no
Preliminary Prospectus, at the time of filing thereof, contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were
made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in
writing by such Underwriter through the Representatives expressly for use in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in
Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time
did not, and as of the Closing Date and as of each Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the
light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating
to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing
Disclosure Package that is required to be included in the Prospectus has been omitted therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Issuer Free
Writing Prospectus. </I>Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including its agents and representatives, other than the Underwriters in their capacity as such) has not prepared, made, used,
authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any &#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer
to buy the Shares (each such communication by the Company or its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not
constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134 under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in
writing in advance by the Representatives. Each such Issuer Free Writing Prospectus complies in all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities
Act (to the extent required thereby) and (except as expressly set forth in such Issuer Free Writing Prospectus) does not conflict with the information contained in the Registration Statement or the Pricing Disclosure Package, and, when taken
together with the Preliminary Prospectus filed prior to the first use of such Issuer Free Writing Prospectus, did not, and as of the Closing Date and as of each Additional Closing Date, as the case </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which
they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in
conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and
agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) [Reserved] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials. </I>The
Company (i)&nbsp;has not alone engaged in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications other than
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications with the consent of the Representatives (x)&nbsp;with entities that are qualified institutional buyers (&#147;QIBs&#148;) within the
meaning of Rule 144A of the Securities Act or institutions that are accredited investors within the meaning of Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities Act (&#147;IAIs&#148;) and otherwise in compliance with the
requirements of Section&nbsp;5(d) of the Securities Act or (y)&nbsp;with entities that the Company reasonably believed to be QIBs or IAIs and otherwise in compliance with the requirements of Rule 163B under the Securities Act and (ii)&nbsp;has not
authorized anyone other than the Representatives to engage in <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed or approved for distribution any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications in connection with the offering of the Shares. &#147;Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is
a written communication within the meaning of Rule 405 under the Securities Act. Any individual Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication does not conflict with the
information contained in the Registration Statement or the Pricing Disclosure Package, complied in all material respects with the applicable provisions of the Securities Act, and when taken together with the Pricing Disclosure Package as of the
Applicable Time, did not, and as of the Closing Date and as of each Additional Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Registration Statement and
Prospectus.</I> The Registration Statement is an &#147;automatic shelf registration statement&#148; as defined under Rule 405 of the Securities Act that has been filed with the Commission not earlier than three years prior to the date hereof; and no
notice of objection of the Commission to the use of such registration statement or any post-effective amendment thereto pursuant to Rule 401(g)(2) under the Securities Act has been received by the Company. No order suspending the effectiveness of
the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Shares has been initiated or, to the
knowledge of the Company, threatened by the Commission; as of the applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will
comply in all material respects with the Securities Act, and did not and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not
misleading; and as of the date of the Prospectus and any amendment or supplement thereto and as of the Closing Date and as of each Additional Closing Date, as the case may be, the Prospectus complied and will comply in all material respects with the
Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
provided that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter
furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such
information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
<I>Incorporated Documents</I>. The documents incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements
of the Exchange Act, and none of such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading; and any further documents so filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to
the requirements of the Exchange Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not
misleading. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Financial Statements</I>. The financial statements (including the related notes thereto) of the Company
and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act and the
Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of its operations and the changes in its cash flows for the
periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#147;GAAP&#148;) applied on a consistent basis throughout the periods covered thereby, except in the
case of any unaudited, interim financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission, and any
supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; and the other financial information included or incorporated by reference
in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown
thereby; and there are no disclosures included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package or the Prospectus regarding <FONT STYLE="white-space:nowrap">&#147;non-GAAP</FONT> financial measures&#148; (as
such term is defined by the rules and regulations of the Commission) comply with Regulation G of the Exchange Act and Item 10 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> of the Securities Act, to the extent applicable. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Material Adverse Change.</I> Since the date of the most recent financial statements of the Company included or
incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any material change in the capital stock (other than the issuance of shares of Common Stock upon exercise of
stock options or vesting of awards described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure Package and the Prospectus), short-term debt
or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any development
that would reasonably be expected to result in a material adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of the Company and its subsidiaries taken as a whole; (ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary
course of business) that is material to the Company and its subsidiaries taken as a whole or incurred any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither
the Company nor any of its subsidiaries has sustained any loss or interference with its business that is material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not
covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing
Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Organization and Good Standing.</I> The Company and each of its subsidiaries
have been duly organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective
ownership or lease of property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged,
except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, have a material adverse effect on the business, properties, management, financial position,
stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#147;Material Adverse Effect&#148;). The Company does
not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21 to the Registration Statement. The subsidiaries listed in Schedule 2 to this Agreement are the only significant
subsidiaries of the Company. Since inception Akero Securities Corporation, a wholly owned subsidiary of the Company, has not conducted, and does not currently conduct, any operations, has not had and does not have any employees and has been and is
engaged exclusively in buying, selling, dealing in and holding publicly-traded securities on its own behalf and not as a broker. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Capitalization.</I> The Company has an authorized capitalization as set forth in the Registration Statement, the Pricing
Disclosure Package and the Prospectus under the heading &#147;Description of Capital Stock&#148;; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights; except as described in or expressly contemplated by the Registration Statement, the Pricing Disclosure
Package and the Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options to acquire, or instruments convertible into or exchangeable for, any shares
of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or any such
subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in the Registration Statement, the Pricing
Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly authorized and issued, are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> (except, in the case of any foreign subsidiary, for directors&#146; qualifying shares) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security
interest, restriction on voting or transfer or any other claim of any third party. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Stock Options. </I>With respect to the stock options (the &#147;Stock
Options&#148;) granted pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#147;Company Stock Plans&#148;), (i) each Stock Option intended to qualify as an &#147;incentive stock option&#148; under
Section&nbsp;422 of the Internal Revenue Code of 1986, as amended (the &#147;Code&#148;) so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be
effective by all necessary corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes
or written consents, and the award agreement governing such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all
other applicable laws and regulatory rules or requirements, including the rules of the Nasdaq Global Select Market (the &#147;Nasdaq Market&#148;) and any other exchange on which the Company&#146;s securities are traded, and (iv)&nbsp;each such
grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company and disclosed in the Company&#146;s filings with the Commission in accordance with the Exchange Act and all other
applicable laws. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public
announcement of material information regarding the Company or its subsidiaries or their results of operations or prospects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver this Agreement and to
perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly
taken. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Underwriting Agreement. </I>This Agreement has been duly authorized, executed and delivered by the Company.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <I>The Shares. </I>The Shares to be issued and sold by the Company hereunder have been duly authorized by the Company
and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing
Disclosure Package and the Prospectus; and the issuance of the Shares is not subject to any preemptive or similar rights that have not been duly and validly waived or satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <I>Listing. </I>The Shares are listed on the Nasdaq Market. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <I>Description of the Underwriting Agreement.</I> This Agreement conforms in all material respects to the description
thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <I>No Violation or
Default.</I> Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with
notice or lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which
the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any of the property or assets of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in violation of any law or
statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such default or violation that would not, individually or in the
aggregate, have a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <I>No Conflicts. </I>The execution, delivery and performance by the
Company of this Agreement, the issuance and sale of the Shares and the consummation by the Company of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or result in a
breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right
or assets of the Company or any of its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its
subsidiaries is bound or to which any of the property, right or assets of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or
similar organizational documents of the Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority,
except, in the case of clauses (i)&nbsp;and (iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <I>No Consents Required.</I> No consent, filing, approval, authorization, order, license, registration or qualification of
or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation of the transactions
contemplated by this Agreement, except for the registration of the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory
Authority, Inc. (&#147;FINRA&#148;), Nasdaq and under applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <I>Legal Proceedings.</I> There are no legal, governmental or regulatory investigations, actions, demands, claims, suits,
arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company or any of its subsidiaries is or may be a party or to which any property of the Company or any of its subsidiaries is or may be the subject that, individually
or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; no such Actions are threatened or, to the knowledge of the Company, contemplated by any
governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure Package or the
Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be
filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as exhibits to the Registration Statement or described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <I>Independent Accountants</I>. Deloitte&nbsp;&amp; Touche LLP, who
has certified certain financial statements of the Company and its subsidiaries is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission
and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <I>Title to Real and Personal Property</I>. The Company and its
subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property and assets that are material to the respective
businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of
such property by the Company and its subsidiaries or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <I>Title to Intellectual Property</I>. The Company and its subsidiaries own, or possess valid and enforceable licensed
rights to use, all material patents, patent applications, trademarks, service marks, trade names, trademark registrations, service mark registrations, trade dress, designs, data, database rights, Internet domain names, copyrights, works of
authorship, licenses, proprietary information and <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) necessary for the
conduct of their respective businesses as currently conducted and as proposed to be conducted (collectively, &#147;Intellectual Property&#148;), and, to the Company&#146;s knowledge, the conduct of their respective businesses does not and will not
infringe, misappropriate or otherwise conflict in any material respect with any such rights of others. The Intellectual Property of the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in
part, and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. The Company and its subsidiaries have not received any notice of any claim of infringement, misappropriation with any intellectual property
rights of another, and the Company is unaware of any facts which would form a reasonable basis for any such notice or claim. To the Company&#146;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property, except
for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus (&#147;Disclosure Documents&#148;) as owned by or
licensed to the Company or its subsidiaries; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there is no
pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual Property, and the Company is unaware of any facts which would form a
reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware of any facts which would form a reasonable basis for any such
action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or its subsidiaries infringe, misappropriate, or otherwise violate, or would, upon the commercialization of any product or service described in the Disclosure Documents as
under development, infringe, misappropriate, or otherwise violate, any intellectual property rights of others, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company
and its subsidiaries have complied with the terms of each agreement pursuant to which Intellectual Property has been licensed to the Company or its subsidiaries, and all such agreements are in full force and effect. To the Company&#146;s knowledge,
there are no material defects in any of the patents or patent applications included in the Intellectual Property. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property,
including the execution of appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and to the Company&#146;s knowledge, no employee of the Company is in or has been in
violation of any term of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement,
nondisclosure agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company. To the Company&#146;s knowledge, the duty of candor and good faith as
required by the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
United States Patent and Trademark Office during the prosecution of the United States patents and patent applications included in the Intellectual Property have been complied with; and in all
foreign offices having similar requirements, all such requirements have been complied with. None of the Company owned Intellectual Property or technology (including information technology and outsourced arrangements) employed by the Company or its
subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any contractual obligation binding on the Company or its subsidiaries or any of their respective officers, directors or employees or otherwise in
violation of the rights of any persons. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <I>Trade Secrets</I>. The Company and its subsidiaries have taken reasonable
and customary actions to protect their rights in and prevent the unauthorized use and disclosure of material trade secrets and confidential business information (including material confidential source code, ideas, research and development
information, <FONT STYLE="white-space:nowrap">know-how,</FONT> formulas, compositions, technical data, designs, drawings, specifications, research records, records of inventions, test information, financial, marketing and business data, customer and
supplier lists and information, pricing and cost information, business and marketing plans and proposals) owned by the Company and its subsidiaries, and, to the knowledge of the Company, there has been no unauthorized use or disclosure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <I>IT Assets</I>. Except as could not reasonably be expected to have a Material Adverse Effect (i)&nbsp;the computers,
software, servers, networks, data communications lines, and other information technology systems owned, licensed, leased or otherwise used by the Company or its subsidiaries (excluding any public networks) (collectively, the &#147;IT Assets&#148;)
operate and perform as is necessary for the operation of the business of the Company and its subsidiaries as currently conducted and as proposed to be conducted as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, and (ii)&nbsp;such IT Assets are not infected by viruses, disabling code or other harmful code. The Company and its subsidiaries have at all times implemented and maintained all reasonably necessary controls, policies, procedures, and
safeguards to maintain and protect their confidential information and the integrity, continuous operation, redundancy and security of all IT Assets and data (including all Sensitive Data (defined below) sensitive, confidential or regulated data
(&#147;Confidential Data&#148;) used in connection with their businesses, and there have been no breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been remedied without material cost or liability
or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <I>Data Privacy and Security Laws</I>. The Company and its subsidiaries and, to the Company&#146;s knowledge, their
respective agents and subcontractors, are, and at all prior times were, in compliance in all material respects with all applicable state, federal, and international data privacy and data security laws, regulations, and related rules and
requirements, including without limitation the Health Insurance Portability and Accountability Act of 1996 and the HITECH Act (collectively &#147;HIPAA&#148;), the European Union General Data Protection Regulation (&#147;GDPR&#148;) (EU 2016/679)
(collectively, the &#147;Privacy Laws&#148;). To address compliance with the Privacy Laws, the Company and its subsidiaries have in place, comply with, and take commercially reasonable steps to achieve compliance in all material respects with their
policies and procedures relating to data privacy and security and the collection, storage, use, disclosure, handling, and transfer of Personal Data (the &#147;Policies&#148;). &#147;Personal Data&#148; means (i)&nbsp;a natural person&#146;s name,
street address, telephone number, <FONT STYLE="white-space:nowrap">e-mail</FONT> address, photograph, social security number or tax identification number, driver&#146;s license number, passport number, credit card number, bank information, or
customer or account number; (ii)&nbsp;any other piece of information that identifies such natural person and is defined in or addressed by Privacy Laws. At all times, the Company and its subsidiaries have made all disclosures to users or customers
required by applicable Privacy Laws, and none of such disclosures </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable Privacy Laws. The Company further certifies that (a)&nbsp;neither it nor
any subsidiary at any time: (i)&nbsp;has received receive written notice of any actual or potential liability, including, but not limited to security or data privacy breaches or other unauthorized or improper access to, use of, or destruction of its
Sensitive Data (defined below) owned or controlled by the Company or its subsidiaries, under or relating to, or actual or potential violation of, any of the Privacy Laws, and has no knowledge of any event or condition that would reasonably be
expected to result in any such notice; (ii)&nbsp;other than pursuant to its ongoing compliance efforts in the ordinary course of business, is currently conducting, subject to, or paying, in whole or in part, any material investigation, remediation,
or other corrective action resulting from the Company&#146;s or its subsidiaries&#146; <FONT STYLE="white-space:nowrap">non-compliance</FONT> with any Privacy Law; or (iii)&nbsp;is a party to any order, decree, settlement agreement, or judgment from
a governmental entity that imposes any obligation or liability under any Privacy Law; and (b)&nbsp;it is not aware of any specific events rendering any of the foregoing reasonably likely to occur. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <I>No Complaints</I>. There is no complaint or audit, proceeding, investigation (formal or informal) or claim currently
pending against the Company or its subsidiaries, or to the knowledge of the Company, any of its customers (specific to the customer&#146;s use of the products or services of the Company) by any state Attorney General or related office, the Federal
Trade Commission, the U.S. Department of Health and Human Services and any office contained therein (&#147;HHS&#148;), or any similar authority in any jurisdiction other than the United States or any other governmental entity, or by any person in
respect of the collection, use or disclosure of Sensitive Data (defined below) by the Company or its subsidiaries, and, to the knowledge of the Company, no such complaint, audit, proceeding, investigation or claim is threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <I>FDA Compliance</I>. The Company: (A)&nbsp;is and at all times has been in material compliance with all statutes, rules
or regulations of the U.S. Food and Drug Administration (&#147;<U>FDA</U>&#148;) and other comparable governmental entities applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing,
labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or distributed by the Company (&#147;Applicable Laws&#148;); (B) has not received any FDA Form 483, notice of adverse
finding, warning letter, untitled letter or other correspondence or notice from the FDA or any comparable governmental entity alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances,
exemptions, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#147;Authorizations&#148;); (C) possesses all material Authorizations and such Authorizations are valid and in full force and effect and
the Company is not in material violation of any term of any such Authorizations; (D)&nbsp;has not received notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or any comparable
governmental entity or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any comparable governmental entity or third party is
considering any such claim, litigation, arbitration, action, suit, investigation or proceeding; (E)&nbsp;has not received notice that the FDA or any comparable governmental entity has taken, is taking or intends to take action to limit, suspend,
modify or revoke any material Authorizations and has no knowledge that the FDA or any comparable governmental entity is considering such action; and (F)&nbsp;has filed, obtained, maintained or submitted all material reports, documents, forms,
notices, applications, records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements
or amendments were materially complete and correct on the date filed (or were corrected or supplemented by a subsequent submission). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <I>Studies, Tests and Preclinical and Clinical Trials</I>. The studies,
tests and preclinical and clinical trials conducted by or on behalf of the Company, to the Company&#146;s knowledge, were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and
controls pursuant to accepted professional scientific standards and all Authorizations and Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and any
applicable rules, regulations and policies of the jurisdiction in which such trials and studies are being conducted; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Pricing Disclosure
Package and the Prospectus are, to the Company&#146;s knowledge, accurate and complete in all material respects and fairly present the data derived from such studies, tests and trials; except to the extent disclosed in the Registration Statement,
the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes reasonably call into question the study, test, or trial results described or referred to in the
Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical stage of development; and, except to the extent disclosed in the Registration Statement, the
Pricing Disclosure Package or the Prospectus, the Company has not received any notices or correspondence from the FDA or any comparable governmental entity requiring the termination or suspension of any studies, tests or preclinical or clinical
trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and implementation of such trials, copies of which communications have been made available to you.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <I>Compliance with Health Care Laws</I>. The Company and its subsidiaries, and to the Company&#146;s knowledge their
respective officers, directors, employees and agents, are, and at all times have been, in compliance in all material respects with all Health Care Laws, to the extent applicable to the business of the Company and its subsidiary. For purposes of this
Agreement, &#147;Health Care Laws&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act and the regulations promulgated thereunder; (ii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including,
without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal False Statements Law (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18 U.S.C. Sections 286, 287, 1035, 1347, and 1349 the health care fraud criminal provisions under HIPAA, the civil monetary penalties law (42 U.S.C.
<FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusions law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> the Physician Payments Sunshine Act (42 U.S.C
<FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h),</FONT> and the laws governing U.S. government funded or sponsored healthcare programs; (iii)&nbsp;similar local, state, federal, national, supranational and foreign laws the directives and
regulations promulgated pursuant to such statutes and any state or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> counterpart thereof; and (iv)&nbsp;all other local, state, federal, national and supranational laws applicable to the regulation of
the ownership, testing, development, manufacture, packaging, processing, use, distribution, marketing, advertising, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product under development, manufactured or
distributed by or for the Company or any of its Subsidiaries. Neither the Company nor any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from
any court or arbitrator or governmental or regulatory authority or third party alleging that any product operation or activity is in violation of any Health Care Laws nor, to the Company&#146;s knowledge, is any such claim, action, suit, proceeding,
hearing, enforcement, investigation, arbitration or other action threatened. The Company, and to the Company&#146;s knowledge, its subsidiaries, have filed, maintained or submitted all material reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were complete and accurate on
the date filed in all material respects (or were corrected or supplemented by a subsequent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
submission). Neither the Company, any of its subsidiaries, nor, to the Company&#146;s knowledge, any of their respective employees, officers, directors, or agents is a party to any corporate
integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, neither the Company, any of its subsidiaries nor any of their
respective employees, officers, directors, or agents has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental
inquiry, investigation, proceeding, or other similar action that could reasonably be expected to result in debarment, suspension, or exclusion. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <I>No Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among the Company or any of
its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the other, that is required by the Securities Act to be described in each of the
Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <I>Investment Company Act</I>. The Company is not and, after giving effect to the offering and sale of the Shares and the
application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#147;investment company&#148; or an entity &#147;controlled&#148; by an
&#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Investment Company Act&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <I>Taxes.</I> The Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax
returns required to be paid or filed through the date hereof except for taxes being contested in good faith and for which reserves in accordance with GAAP have been taken; and except as otherwise disclosed in each of the Registration Statement, the
Pricing Disclosure Package and the Prospectus, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets that would
individually or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <I>Licenses and Permits.</I> To the Company&#146;s
knowledge, the Company and its subsidiaries possess all licenses, certificates, permits and other authorizations, other than with respect to its Intellectual Property, issued by, and have made all declarations and filings with, the appropriate and
applicable federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their respective properties or the conduct of their respective businesses as described in each of the Registration
Statement, the Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, have a Material Adverse Effect; and neither the Company nor any of its subsidiaries has
received notice of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be renewed in the ordinary course, except
where such revocation, modification or nonrenewal would not reasonably be expected to have a Material Adverse Effect. To the Company&#146;s knowledge, no party granting any such licenses, certificates, permits and other authorizations has taken any
action to limit, suspend or revoke the same in any material respect. The Company and its subsidiaries have filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments as required and that all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were corrected or
supplemented by a subsequent submission) as required for maintenance of their licenses, certificates, permits and other authorizations that are necessary for the conduct of their respective businesses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <I>No Labor Disputes.</I> No labor disturbance by or dispute with
employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of
its or its subsidiaries&#146; principal suppliers, contractors or customers, except as would not have a Material Adverse Effect. Neither the Company nor any of its subsidiaries has received any notice of cancellation or termination with respect to
any collective bargaining agreement to which it is a party. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <I>Certain Environmental Matters. </I>(i)&nbsp;The
Company and its subsidiaries (x)&nbsp;are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws (including common law), rules, regulations, requirements, decisions, judgments, decrees, orders and other
legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;Environmental
Laws&#148;); (y) have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and
(z)&nbsp;have not received notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or release of
hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice, and (ii)&nbsp;there are no costs or liabilities associated with
Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect; and (iii)&nbsp;(x) there is no proceeding that is pending, or that is known to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other than such
proceeding regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental Laws, or
liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that could reasonably be expected to have a material effect on the capital expenditures, earnings or
competitive position of the Company and its subsidiaries, and (z)&nbsp;none of the Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <I>Hazardous Materials</I>. There has been no storage, generation, transportation, use, handling, treatment, Release or
threat of Release of Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries, any other entity (including any predecessor) for whose acts or omissions the
Company or any of its subsidiaries is or would reasonably be expected to be liable) at, on, under or from any property or facility now or previously owned, operated or leased by the Company or any of its subsidiaries, or at, on, under or from any
other property or facility, in violation of any Environmental Laws or in a manner or amount or to a location that could reasonably be expected to result in any liability under any Environmental Law, except for any violation or liability which would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. &#147;Hazardous Materials&#148; means any material, chemical, substance, waste, pollutant, contaminant, compound, mixture, or constituent thereof, in
any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing materials, naturally occurring radioactive materials, brine, and drilling mud,
regulated or which can give rise to liability under any Environmental Law. &#147;Release&#148; means any spilling, leaking, seepage, pumping, pouring, emitting, emptying, discharging, injecting, escaping, leaching, dumping, disposing, depositing,
dispersing, or migrating in, into or through the environment, or in, into from or through any building or structure. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <I>Compliance with ERISA.</I> (i)&nbsp;Each employee benefit plan,
within the meaning of Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not
incorporated, that is under common control with the Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the
Internal Revenue Code of 1986, as amended (the &#147;Code&#148;)) would have any liability (each, a &#147;Plan&#148;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations,
including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant
to a statutory or administrative exemption; (iii)&nbsp;for each Plan that is subject to the funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to
satisfy the minimum funding standards (within the meaning of Section&nbsp;302 of ERISA or Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning
of Section&nbsp;303(i) of ERISA) and no Plan that is a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and
305 of ERISA)&nbsp;(v) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#147;reportable event&#148; (within
the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code is so qualified,
and nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled Group has incurred, nor reasonably expects to incur, any liability
under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a Plan (including a &#147;multiemployer plan&#148; within the meaning
of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the following events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount of contributions required to be made to all Plans by the Company or
its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group affiliates compared to the amount of such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed
fiscal year; or (B)&nbsp;a material increase in the Company and its subsidiaries&#146; &#147;accumulated post-retirement benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic
<FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such obligations in the Company and its subsidiaries&#146; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in
(i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate, have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn)
<I>Disclosure Controls</I>. The Company and its subsidiaries maintain an effective system of &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with
the requirements of the Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the
time periods specified in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions
regarding required disclosure. The Company and its subsidiaries have carried out evaluations of the effectiveness of their disclosure controls and procedures as required by Rule <FONT STYLE="white-space:nowrap">13a-15</FONT> of the Exchange Act.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <I>Accounting Controls.</I> The Company and its subsidiaries maintain
systems of &#147;internal control over financial reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the
supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s general or
specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with
management&#146;s general or specific authorization; and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences and
(v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus fairly presents the information called for in all material
respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses or
significant deficiencies in the Company&#146;s internal controls over financial reporting. The Company&#146;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and
material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely affect the Company&#146;s ability to record, process, summarize and report financial
information; and (ii)&nbsp;to the best knowledge of the Company, any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#146;s internal controls over financial reporting. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <I>eXtensible Business Reporting Language.</I> The interactive data in eXtensible Business Reporting Language included or
incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <I>Insurance. </I>The Company and its subsidiaries have insurance covering their respective properties, operations,
personnel and businesses, including business interruption insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by companies engaged in the same or similar business and which the Company
reasonably believes are adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital
improvements or other expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to
obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <I>No
Unlawful Payments.</I> Neither the Company nor any of its subsidiaries nor any director, officer, or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or
acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit to any foreign or domestic government or regulatory official or employee, including of
any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office;
(iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or anti-corruption laws; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any
unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce, and
will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and anti-corruption laws. Neither the Company nor any of its subsidiaries will use, directly or indirectly, the
proceeds of the offering in furtherance of an offer, payment, promise to pay, or authorization of the payment or giving of money, or anything else of value, to any person in violation of any applicable anti-corruption laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <I>Compliance with Anti-Money Laundering Laws</I>. The operations of the Company and its subsidiaries are and have been
conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all
jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by any governmental or regulatory agency
(collectively, the &#147;Anti-Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with
respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt) <I>No Conflicts
with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries, directors, officers or employees, nor, to the knowledge of the Company, any agent, or affiliate or other person associated with or acting on behalf of the Company or any of
its subsidiaries is an individual or entity (&#147;Person&#148;) that is, or is owned or controlled by one or more Persons that are (i)&nbsp;currently the subject or the target of any sanctions administered or enforced by the U.S. government,
(including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation as a &#147;specially designated national&#148; or
&#147;blocked person&#148;), the United Nations Security Council, the European Union, His Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), or (ii)&nbsp;located, organized or resident in a country
or territory that is the subject or the target of Sanctions, including, without limitation, Cuba, Iran, North Korea, Syria, and the Crimea, <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, and <FONT
STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic regions of Ukraine (each, a &#147;Sanctioned Country&#148;). The Company will not directly or indirectly use the proceeds of the offering of the Shares hereunder, or lend,
contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation,
is the subject or the target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person (including any person participating in
the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. Since the Company&#146;s inception, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any dealings or
transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu) <I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is
currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock or
similar ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv) <I>No Broker&#146;s Fees.</I> Neither the Company nor any of its subsidiaries is a party to any contract, agreement or
understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in connection with the
offering and sale of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww) <I>No Registration Rights</I>. Except as described in the Registration Statement,
the Pricing Disclosure Packages and the Prospectus, no person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the
Commission or the issuance and sale of the Shares, other than those rights that have been duly and validly waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx)
<I>No Stabilization.</I> Neither the Company nor any of its subsidiaries or affiliates has taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the
price of the Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy) <I>Margin Rules</I>. Neither the issuance, sale and delivery of the Shares nor the application
of the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other
regulation of such Board of Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(zz) <I>Forward-Looking Statements.</I> No forward-looking statement (within the
meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed
without a reasonable basis or has been disclosed other than in good faith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(aaa) Statistical and Market Data.</I>
Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the
Prospectus is not based on or derived from sources that are reliable and accurate in all material respects. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb)
<I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of the Company or, to the knowledge of the Company, any of the Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the
Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith (the &#147;Sarbanes-Oxley Act&#148;), including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc) <I>Status under the Securities Act</I>. At the time of filing the
Registration Statement and any post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Shares
and at the date hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ddd) <I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities, convertible securities or
preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62) under the Exchange Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(eee) <I>Cybersecurity; Data Protection</I>. (A)&nbsp;There has been no actual or suspected security breaches or incidents,
unauthorized access or disclosure, or other compromise of or relating to the Company and its subsidiaries&#146; information technology assets and equipment, computers, systems, networks, hardware, software, websites, applications, technology, data
and databases (including the data and information of their respective customers, employees, suppliers, vendors and any third party data maintained, processed or stored by the Company and its subsidiaries, Sensitive Data (defined below) and any such
data processed or stored by third parties on behalf of the Company and its subsidiaries) collectively, &#147;IT Systems and Data&#148;); (B) The IT Systems and Data are adequate for, and operate and perform in all material respects as required in
connection with the operation of the business of the Company and the subsidiaries as currently conducted, free and clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants; and (C)&nbsp;the Company and
its subsidiaries have implemented and maintained appropriate controls, policies, procedures, and administrative, technical, and physical safeguards to maintain and protect their material confidential information and the integrity, continuous
operation, redundancy and security of all IT Systems and Data (including all Personal Data, sensitive, confidential or regulated data (&#147;Sensitive Data&#148;)) reasonably consistent with industry standards and practices or as required by
applicable regulatory standards. The Company and its subsidiaries have been and are presently in material compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or
regulatory authority, internal policies and contractual obligations relating to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(fff) <I>WKSI</I>. The Company is a &#147;well-known seasoned issuer&#148; as defined in Rule 405 of the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4. <U>Further Agreements of the Company</U>. The Company covenants and agrees with each Underwriter that: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Required Filings.</I> The Company will file the final Prospectus with the Commission within the time periods specified
by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; the Company will file promptly all reports and any definitive proxy or
information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the Prospectus and for so long as the delivery of a prospectus is
required in connection with the offering or sale of the Shares; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriters in New York City prior to
10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request. The Company will pay the registration fee for this offering within the time period
required by Rule 456(b)(1) under the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing Date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Delivery of Copies.</I> The Company will deliver, upon request and
without charge, (i)&nbsp;to the Representative, four signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference
therein; and (ii)&nbsp;to each Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many
copies of the Prospectus (including all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term
&#147;Prospectus Delivery Period&#148; means such period of time after the first date of the public offering of the Shares as in the opinion of counsel for the Underwriters a prospectus relating to the Shares is required by law to be delivered (or
required to be delivered but for Rule 172 under the Securities Act) in connection with sales of the Shares by any Underwriter or dealer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Amendments or Supplements, Issuer Free Writing Prospectuses.</I> Before preparing, using, authorizing, approving,
referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company will furnish to the Representatives and counsel for
the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or
supplement to which the Representatives reasonably object. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Notice to the Representatives.</I> The Company will
advise the Representatives promptly, and confirm such advice in writing (which advice may be delivered via electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has
been filed or becomes effective; (iii)&nbsp;when any supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus or any amendment to the Prospectus has been filed or distributed; (iv)&nbsp;of any request by the
Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement or any other request by the Commission for any
additional information including, but not limited to, any request for information concerning any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the
Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package, the
Prospectus or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which
the Prospectus, any of the Pricing Disclosure Package, or any Issuer Free Writing Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact or necessary in order to make the
statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, or any such Issuer Free Writing Prospectus is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company
of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its best efforts to prevent the
issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary Prospectus, any of the Pricing Disclosure Package or the Prospectus or suspending any such qualification of
the Shares and, if any such order is issued, will use its reasonable best efforts to obtain as soon as possible the withdrawal thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Ongoing Compliance.</I> (1)&nbsp;If during the Prospectus Delivery
Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will
promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements
to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and
incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to the Closing
Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure
Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Underwriters and to such
dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the
Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with
law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Blue Sky Compliance.</I> The Company will qualify the Shares for offer and sale under the securities or Blue
Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the Shares; <U>provided</U> that the Company shall not be required to
(i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service of process in any such jurisdiction
or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Earnings
Statement. </I>The Company will make generally available to its securityholders and the Representatives as soon as practicable an earnings statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the
Commission promulgated thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement, it being
understood and agreed that such earning statement shall be deemed to have been made available by the Company if the Company is in compliance with its reporting obligations pursuant to the Exchange Act, if such compliance satisfies the conditions of
Rule 158, and if such earnings statement is made available on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval system (&#147;EDGAR&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Clear Market.</I> For a period of 90 days after the date of the
Prospectus, the Company will not, and will not publicly disclose an intention to, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to
purchase, hedge, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the Commission a registration statement under the Securities Act (other than registration statements on Form <FONT
STYLE="white-space:nowrap">S-8</FONT> under the Securities Act relating to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Securities (as defined below) granted or to be granted pursuant to the terms of any Company Stock Plan disclosed in the
Pricing Disclosure Package relating to any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock <FONT STYLE="white-space:nowrap">(&#147;Lock-Up</FONT> Securities&#148;), or (ii)&nbsp;enter into any swap,
hedging or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by
delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of J.P. Morgan Securities LLC, Morgan Stanley&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C., other than (A)&nbsp;the Shares to be sold
hereunder, (B)&nbsp;any shares of Stock of the Company issued upon the exercise of options outstanding on the date hereof, described in the Registration Statement, the Pricing Disclosure Package, the Prospectus, or, in each case, any document
incorporated by reference therein, and issued under Company Stock Plans disclosed in the Registration Statement, the Pricing Disclosure Package, the Prospectus, or in each case, any document incorporated by reference therein; provided that each
newly appointed director or executive officer that is a recipient of any such shares of Stock shall deliver (if it has not previously delivered) a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement to the Representatives
substantially in the form of Exhibit A hereto, and such shares of Stock will be subject to the terms of such <FONT STYLE="white-space:nowrap">lock-up,</FONT> (C)&nbsp;the grant by the Company of awards under Company Stock Plans as disclosed in the
Registration Statement, the Pricing Disclosure Package, the Prospectus, or, in each case, any document incorporated by reference therein; provided that each newly appointed director or executive officer that is a recipient of any such awards shall
deliver (if it has not previously delivered) a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement to the Representatives substantially in the form of Exhibit A hereto, and such awards will be subject to the terms of such <FONT
STYLE="white-space:nowrap">lock-up,</FONT> (D)&nbsp;up to 5% of the Company&#146;s outstanding securities issued by the Company in connection with mergers, acquisitions or commercial or strategic transactions provided that each newly appointed
director or executive officer that is a recipient execute a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement for the remainder of the Restricted Period in the form of Exhibit A hereto, (E)&nbsp;the filing by the Company of any registration
statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to a Company Stock Plan described in the Registration Statement, the Pricing Disclosure Package, the Prospectus, or, in each case, any document
incorporated by reference therein, (F)&nbsp;the filing by the Company of any registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> or a successor form thereto relating to Company&#146;s <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">&#147;at-the-market&#148;</FONT></FONT> offerings pursuant to that Open Market Sale Agreement, by and between the Company and Jefferies LLC, dated March&nbsp;17, 2023, as amended from time to time (the &#147;ATM
Program&#148;), (G) any shares of Stock sold pursuant to the ATM Program; provided that no sales shall be made until 30 days after the date of this Agreement, or (H)&nbsp;any assistance to a stockholder of the Company in the establishment of a
trading plan by such stockholder pursuant to Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of Stock; provided (x)&nbsp;that such plan does not provide for the transfer of Stock during the <FONT
STYLE="white-space:nowrap">90-day</FONT> period after the date of the Prospectus pursuant to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement between such stockholder and the Underwriter in connection with the Offering (the
<FONT STYLE="white-space:nowrap">&#147;Lock-Up</FONT> Period&#148;), (y) no voluntary public filings or other public announcements of such plan during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period will be made regarding the
establishment of such plan, and any required filings or announcements (which the parties acknowledge is required by the Company under the Exchange Act) include or refer to the restrictions set forth in such
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement and (z)&nbsp;such plan is otherwise permitted to be implemented during the <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>Use of Proceeds.</I> The Company will apply the net proceeds from the
sale of the Shares as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>No Stabilization.</I> Neither the Company nor its affiliates will take, directly or indirectly, without giving effect to
Shares offered by the Underwriters, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Stock. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Company will use its best efforts to list, subject to notice of issuance, the Shares on the
Nasdaq Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I>Reports.</I> During a period of three (3)&nbsp;years from the date of this Agreement, the Company
will furnish to the Representatives, as soon as commercially reasonable after the date on which they are available, copies of all reports or other communications (financial or other) furnished to holders of the Shares, and copies of any reports and
financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports and financial statements to the
Representatives to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis, and Retrieval system. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each
Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Shelf Renewal.</I> If immediately prior to the third anniversary (the &#147;Renewal Deadline&#148;) of the initial
effective date of the Registration Statement, any of the Shares remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do so, a new automatic shelf registration
statement relating to the Shares, in a form satisfactory to the Representatives. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the Renewal Deadline, if it has not already done so, file a
new shelf registration statement relating to the Shares, in a form satisfactory to the Representative, and will use its best efforts to cause such registration statement to be declared effective within 180 days after the Renewal Deadline. The
Company will take all other action necessary or appropriate to permit the issuance and sale of the Shares to continue as contemplated in the expired registration statement relating to the Shares. References herein to the Registration Statement shall
include such new automatic shelf registration statement or such new shelf registration statement, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Certain
Agreements of the Underwriters</U>. Each Underwriter hereby represents and agrees that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) It has not used, authorized
use of, referred to or participated in the planning for use of, and will not use, authorize use of, refer to or participate in the planning for use of, any &#147;free writing prospectus&#148;, as defined in Rule 405 under the Securities Act (which
term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that
contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities Act) that was not included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing
Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c) or Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such
Underwriter and approved by the Company in advance in writing (each such free writing prospectus referred to in clauses (i)&nbsp;or (iii) an &#147;Underwriter Free Writing Prospectus&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) It has not and will not, without the prior written consent of the
Company, use any free writing prospectus that contains the final terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; <I>provided </I>that Underwriters may use a term sheet
substantially in the form of Annex B hereto without the consent of the Company; <I>provided further</I> that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or
substantially concurrent with, the first use of such term sheet. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) It is not subject to any pending proceeding under
Section&nbsp;8A of the Securities Act with respect to the offering contemplated by this Agreement (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Underwritten Shares on the Closing
Date or the Option Shares on an Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be
in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been timely filed with
the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all requests by the Commission for
additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
<I>Representations and Warranties.</I> The representations and warranties of the Company contained herein shall be true and correct on the date hereof and on and as of the Closing Date or an Additional Closing Date, as the case may be; and the
statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or an Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>No Material Adverse Change.</I> No event or condition of a type described in Section&nbsp;3(i) hereof shall have
occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement thereto) and the effect of which in the
judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or an Additional Closing Date, as the case may be, on the terms and in the manner contemplated by
this Agreement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Officers&#146; Certificate.</I> The
Representatives shall have received on and as of the Closing Date or an Additional Closing Date, as the case may be, a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer
of the Company who is satisfactory to the Representatives (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the
representations set forth in Sections 3(b) and 3(f) hereof </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement are true and correct and that the Company has complied in all material
respects with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set forth in paragraphs
(a), (b) and (c)&nbsp;above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Comfort Letters.</I> (i)&nbsp;On the date of this Agreement and on the Closing Date or
the Additional Closing Date, as the case may be, Deloitte&nbsp;&amp; Touche LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in
form and substance reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and
certain financial information contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as
the case may be, shall use a <FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than two business days prior to such Closing Date or such Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Opinion and Negative Assurance Letter of Counsel for the Company.</I> Goodwin Procter LLP, counsel for the Company,
shall have furnished to the Representatives, at the request of the Company, their written opinion, including with respect to certain regulatory matters, and negative assurance letter, dated the Closing Date or the Additional Closing Date, as the
case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)
<I>Opinion of Intellectual Property Counsel for the Company</I>. Marshall, Gerstein&nbsp;&amp; Borun LLP, intellectual property counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written
opinion, dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriters, in form and substance reasonably satisfactory to the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Opinion and Negative Assurance Letter of Counsel for the Underwriters.</I> The Representatives shall have received on
and as of the Closing Date or the Additional Closing Date, as the case may be, an opinion and negative assurance letter of Cooley LLP, counsel for the Underwriters, with respect to such matters as the Representatives may reasonably request, and such
counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <I>No Legal Impediment to Issuance and Sale.</I> No action shall have been taken and no statute, rule, regulation or order
shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares; and
no injunction or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or sale of the Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) <I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date or the Additional Closing Date,
as the case may be, satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as the Representatives may
reasonably request, in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <I>Exchange Listing.</I> The Shares to be delivered on the Closing Date
or the Additional Closing Date, as the case may be, shall have been approved for listing on the Nasdaq Market, subject to official notice of issuance. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The
<FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreements, each substantially in the form of Exhibit A hereto, between you and all executive officers and directors of the Company relating to sales and certain other dispositions of
shares of Stock or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date or the Additional Closing Date, as the case may be. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) [Reserved] </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <I>Additional Documents.</I> On or prior to the Closing Date or the Additional Closing Date, as the case may be, the
Company shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the
provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Indemnification
and Contribution</U>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Indemnification of the Underwriters.</I> The Company agrees to indemnify and hold harmless
each Underwriter, its affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses,
claims, damages and liabilities (including, without limitation, reasonable and documented legal fees and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred), joint
or several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material fact
required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement
thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any materials or information provided to investors by, or with the approval of, the Company, including any road show as defined in Rule 433(h) under the Securities Act (a
&#147;road show&#148;) or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the
statements therein, in light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged
untrue statement or omission made in reliance upon and in conformity with any information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood
and agreed that the only such information furnished by any Underwriter consists of the information described as such in subsection (b)&nbsp;below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Indemnification of the Company.</I> Each Underwriter agrees,
severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or
Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities (including, without limitation, reasonable and documented legal fees
and other expenses incurred in connection with any suit, action, or proceeding or any claim asserted, as such fees and expenses are incurred) that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or
omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the Registration Statement, the Prospectus
(or any amendment or supplement thereto), any Preliminary Prospectus, any Issuer Free Writing Prospectus, any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show or any
Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the
Prospectus furnished on behalf of each Underwriter: the concession figure appearing in the third paragraph under the caption &#147;Underwriting&#148; and the information contained in the eighteenth paragraph under the caption &#147;Underwriting.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory
investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;9, such person (the &#147;Indemnified Person&#148;) shall
promptly notify the person against whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have
under the preceding paragraphs of this Section&nbsp;9 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to
notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;9. If any such proceeding shall be brought or asserted against an
Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel
to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the fees and expenses in such proceeding
and shall pay the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such
counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a reasonable time to retain
counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the
Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be
inappropriate due to actual or potential differing interest between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same jurisdiction, be liable for the
reasonable and documented fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such reasonable and documented fees and expenses shall be paid or reimbursed as they are
incurred. Any such separate firm for any Underwriter, its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by J.P. Morgan Securities LLC, Morgan Stanley&nbsp;&amp; Co. LLC, Jefferies LLC
and Evercore Group L.L.C. and any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with
such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested
that an Indemnifying Person reimburse the Indemnified Person for reasonable and documented fees and expenses of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without
its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such
request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could
have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such
Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;and (b) above is unavailable to an
Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the
amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the
Underwriters on the other, from the offering of the Shares or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in
clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other
relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received
by the Company from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate
offering price of the Shares. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or prevent such statement
or omission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Limitation on Liability.</I> The Company and the Underwriters agree that it would not be just and
equitable if contribution pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take
account of the equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed
to include, subject to the limitations set forth above, any reasonable and documented legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of paragraphs (d)&nbsp;and
(e), in no event shall an Underwriter be required to contribute </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the Shares exceeds the amount of any
damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f) of the
Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The Underwriters&#146; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several in proportion to their
respective purchase obligations hereunder and not joint. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT>
Remedies.</I> The remedies provided for in this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after
the execution and delivery of this Agreement and on or prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date: (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of
the New York Stock Exchange or the Nasdaq Market; (ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or
(iv)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and
adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the
Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10. <U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) If, on the Closing Date or the Additional Closing Date, as the case may be, any Underwriter defaults on its obligation to
purchase the Shares that it has agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Shares by other persons satisfactory to the
Company on the terms contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Shares, then the Company
shall be entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Shares on such terms. If other persons become obligated
or agree to purchase the Shares of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date or the Additional Closing Date, as the case may be, for up to
five full business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the
Company agrees to promptly prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement
unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Shares that a defaulting Underwriter agreed but failed to purchase. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If, after giving effect to any arrangements for the purchase of the
Shares of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the
Closing Date or the Additional Closing Date, as the case may be, does not exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Shares to be purchased on such date, then the Company shall have the right to require
each <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter to purchase the number of Shares that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Shares that
such Underwriter agreed to purchase on such date) of the Shares of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) If, after giving effect to any arrangements for the purchase of the Shares of a defaulting Underwriter or Underwriters by
the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Shares that remain unpurchased on the Closing Date or the Additional Closing Date, as the case
may be, exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Shares to be purchased on such date, or if the Company shall not exercise the right described in paragraph (b)&nbsp;above, then this Agreement or, with
respect to any Additional Closing Date, the obligation of the Underwriters to purchase Shares on the Additional Closing Date, as the case may be, shall terminate without liability on the part of the
<FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without liability on the part of the Company, except that the Company will continue to be liable for the
payment of expenses as set forth in Section&nbsp;11 hereof (other than with respect to the defaulting underwriter(s)) and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain in effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the Company or any <FONT
STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11. <U>Payment of Expenses</U><I>.</I>
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the
Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the
Shares and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, the Preliminary Prospectus, any Issuer Free Writing Prospectus, any Pricing
Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the reasonable and
documented fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Shares under the state or foreign securities or blue sky laws of such jurisdictions as the
Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum and any &#147;Canadian wrapper&#148; (including the related reasonable and documented fees and expenses of counsel for the Underwriters);&nbsp;(v)
the cost of preparing stock certificates; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and application fees incurred in connection with any filing with, and clearance of the offering by FINRA;
(viii)&nbsp;all expenses incurred by the Company in connection with any &#147;road show&#148; presentation to potential investors, provided however, that the Underwriters will pay all of the travel, lodging and other expenses of the Underwriters or
any of their employees incurred by them in connection with the &#147;road show&#148;, and provided, further, that the Company and the Underwriters will each pay 50% of the cost of any aircraft chartered to be used in connection with such road show
by both the Company and the Underwriters; and (ix)&nbsp;all expenses and application fees related to the listing of the Shares on the Nasdaq Market; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If (i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9,
(ii) the Company for any reason fails to tender the Shares for delivery to the Underwriters (other than by reason of a default by any Underwriter) or (iii)&nbsp;the Underwriters decline to purchase the Shares for any reason permitted under this
Agreement, the Company agrees to reimburse the Underwriters for all <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel) reasonably
incurred by the Underwriters in connection with this Agreement and the offering contemplated hereby. For avoidance of doubt, it is understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by an Underwriter that
defaults on its obligations to purchase the Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12. <U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to
the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing
in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Shares from any Underwriter shall be
deemed to be a successor merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13. <U>Survival</U>. The respective indemnities, rights of contribution,
representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant hereto shall
survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or the directors, officers,
controlling persons or affiliates referred to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14. <U>Certain Defined Terms</U>. For purposes of this Agreement,
(a)&nbsp;except where otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means any day other than a day on which banks are permitted
or required to be closed in New York City; (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act; and (d)&nbsp;the term &#147;significant subsidiary&#148; has the meaning set forth in Rule <FONT
STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act. In the event that the Company has only one subsidiary, then all references herein to &#147;subsidiaries&#148; of the Company
shall be deemed to refer to such single subsidiary, mutatis mutandis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15. <U>Compliance with USA Patriot Act</U>. In accordance with the
requirements of the USA Patriot Act (Title III of Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their
respective clients, including the Company, which information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be deemed to have been duly
given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) <FONT
STYLE="white-space:nowrap">622-8358);</FONT> c/o Morgan Stanley&nbsp;&amp;&nbsp;Co. LLC, 1585&nbsp;Broadway, New York, New York&nbsp;10036, Attention: Equity Syndicate Desk, with a copy to the Legal Department; c/o Jefferies LLC, 520 Madison Avenue,
New York, New York 10022, Attention: Global Head of Syndicate; and c/o Evercore Group L.L.C., 55 East 52nd Street, 35th Floor, New York, New York 10055, Attention: ECM, General Counsel. Notices to the Company shall be given to it at Akero
Therapeutics, Inc., 601 Gateway Boulevard, Suite 350, South San Francisco, California 94080; Attention: President. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <I>Governing Law.</I> This Agreement and any claim, controversy or
dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <I>Waiver of Jury Trial</I>. Each of the parties hereto waives any right to trial by jury in any legal proceeding arising
out of or relating to this Agreement or the transactions contemplated hereby. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <I>Recognition of the U.S. Special
Resolution Regimes</I>. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding
under a U.S. Special Resolution Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special
Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;16(g): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in accordance with, 12
U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b);
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b);
or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
382.2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R.
&#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit
Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <I>Counterparts.</I> This Agreement may be signed in counterparts (which
may include counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail
(including any electronic signature complying with the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act or other applicable law, e.g., www. Docusign.com) or other transmission method any counterpart so delivered shall be deemed to
have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <I>Amendments or Waivers.</I> No
amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part of, or
to affect the meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <I>Integration. </I>This Agreement supersedes all prior
agreements and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">AKERO THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Andrew Cheng</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Andrew Cheng</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Accepted: As of the date first written above</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J. P. MORGAN SECURITIES LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MORGAN
STANLEY&nbsp;&amp; CO. LLC</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">EVERCORE GROUP
L.L.C.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">For themselves and on behalf of the several Underwriters listed in Schedule 1 hereto.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">J.P. MORGAN SECURITIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Ke</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: David Ke</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MORGAN STANLEY&nbsp;&amp; CO. LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Kalli Dircks</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Kalli Dircks</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Brinkman</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Name: Michael Brinkman</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Managing Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">EVERCORE GROUP L.L.C.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Maren Winnick</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Maren Winnick</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP>Title: Senior Managing Director</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Number&nbsp;of&nbsp;Shares</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,850,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3,080,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,310,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,760,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 2 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Significant Subsidiaries </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Akero
Securities Corporation </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">a. <B>Pricing Disclosure Package</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">b. <B>Pricing Information Provided Orally by Underwriters</B> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Public Offering Price: $29.00 per Share </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Number of Underwritten Shares: 11,000,000 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Number of Option Shares: 1,650,000 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Akero Therapeutics, Inc. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Term Sheet </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">[&#149;], 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">J.P. MORGAN SECURITIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MORGAN STANLEY&nbsp;&amp; CO. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EVERCORE GROUP L.L.C. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">the several Underwriters listed in </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Schedule 1 to the
Underwriting </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Agreement referred to below </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o J.P. Morgan
Securities LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">383 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10179
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Morgan Stanley&nbsp;&amp; Co. LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1585 Broadway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10036 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">520 Madison Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10022 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">c/o Evercore Group L.L.C. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">55 East 52nd Street </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, New York 10055 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Akero Therapeutics, Inc. &#151; Public Offering </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned, a
director, officer or securityholder of Akero Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;), understands that you, as representatives (the &#147;Representatives&#148;) of the several Underwriters, propose to enter into an
Underwriting Agreement (the &#147;Underwriting Agreement&#148;) with the Company, providing for the public offering (the &#147;Public Offering&#148;) by the several Underwriters named in Schedule 1 to the Underwriting Agreement (the
&#147;Underwriters&#148;), of common stock, par value $0.0001 per share (&#147;Common Stock&#148;) of the Company (the &#147;Securities&#148;). Capitalized terms used herein and not otherwise defined shall have the meanings set forth in the
Underwriting Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the Underwriters&#146; agreement to purchase and make the Public Offering of the Securities,
and for other good and valuable consideration receipt of which is hereby acknowledged, the undersigned hereby agrees that, without the prior written consent of the Representatives on behalf of the Underwriters, the undersigned will not, and will not
cause any direct or indirect affiliate to, during the period beginning on the date of this letter agreement (this &#147;Letter Agreement&#148;) and ending at the close of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
business 90 days after the date of the final prospectus supplement relating to the Public Offering (the &#147;Prospectus&#148;) (such period, the &#147;Restricted Period&#148;), (1) offer,
pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, hedge, lend or otherwise transfer or dispose of, directly or indirectly, any shares of
Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock (including without limitation, Common Stock or such other securities which may be deemed to be beneficially owned by the undersigned in accordance with
the rules and regulations of the Securities and Exchange Commission and securities which may be issued upon exercise of a stock option or warrant), (2) enter into any hedging, swap or other agreement or transaction that transfers, in whole or in
part, any of the economic consequences of ownership of the Common Stock or such other securities, whether any such transaction described in clause (1)&nbsp;or (2) above is to be settled by delivery of Common Stock or such other securities, in cash
or otherwise (3)&nbsp;make any demand for or exercise any right with respect to the registration of any shares of Common Stock or any security convertible into or exercisable or exchangeable for Common Stock (and, for the avoidance of doubt, the
undersigned hereby waives any and all notice requirements and rights with respect to the registration of any securities pursuant to any agreement, instrument, understanding or otherwise, including any stockholders or registration rights agreement or
similar agreement, to which the undersigned is a party or under which the undersigned is entitled to any right or benefit) or (4)&nbsp;publicly disclose the intention to do any of the foregoing, in each case other than: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(A)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Securities, if any, to be sold by the undersigned pursuant to the Underwriting Agreement,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(B)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">sales or transfers of shares of Common Stock acquired in open market transactions after the consummation of the
Public Offering, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of shares of Common Stock (i)&nbsp;as a bona fide gift or gifts, (ii)&nbsp;by will, other
testamentary document or intestate succession to the legal representative, heir, beneficiary or a member of the immediate family of the undersigned in a transaction involving a disposition for value or (iii)&nbsp;by operation of law, such as
pursuant to a qualified domestic order or as required by a divorce settlement, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is an individual, transfers of shares of Common Stock or any security directly or indirectly
convertible into Common Stock in a transaction not involving a disposition for value to any trust for the direct or indirect benefit of the undersigned or the immediate family of the undersigned, or limited partnerships the partners of which are the
undersigned and/or the immediate family members of the undersigned, in each case for estate planning purposes, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a trust, distributions of shares of Common Stock or any security directly or indirectly
convertible into Common Stock to its beneficiaries in a transaction not involving a disposition for value, </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">if the undersigned is a corporation, limited liability company, partnership (whether general, limited or
otherwise) or other entity, distribution of shares of Common Stock or any security directly or indirectly convertible into Common Stock to current or former members, stockholders, limited partners, general partners, subsidiaries or affiliates (as
defined in Rule 405 promulgated under the Securities Act of 1933, as amended) of the undersigned or to any investment fund or other entity that controls or manages the undersigned (including, for the avoidance of doubt, a fund managed by the same
manager or managing member or general partner or management company or by an entity controlling, controlled by, or under common control with such manager or managing member or general partner or management company as the undersigned or who shares a
common investment advisor with the undersigned) in a transaction not involving a disposition for value, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(G)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of shares of Common Stock to the Company in connection with the exercise of options, warrants or
other rights to acquire Common Stock or any security convertible into or exercisable for Common Stock of the Company by way of net exercise and/or to cover withholding tax obligations in connection with such exercise pursuant to an employee benefit
plan, option, warrant or other right disclosed in the Prospectus, provided that any such shares issued upon exercise of such option, warrant or other right shall be subject to the restrictions set forth herein; <I>provided</I> that no public report
or filing required to be made under Section&nbsp;16(a) of the Exchange Act or other public filing, report or announcement shall be required or shall be voluntarily made during the period beginning on the date hereof and continuing to and including
the date that is 30 days after the date of the Prospectus (the &#147;30 Day Period&#148;), and after such 30<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> day, if the undersigned is required to file a report under Section&nbsp;16(a) of the
Exchange Act during the Restricted Period, the undersigned shall clearly indicate in the footnotes thereto that such transfer is pursuant to the circumstances described in this clause (G), and <I>provided</I>, <I>further</I> that no other public
announcement shall be made voluntarily in connection with such transfer; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(H)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">transfers of shares of Common Stock to a bona fide third party pursuant to a merger, consolidation, tender
offer or other similar transaction made to all holders of Common Stock and involving a &#147;Change of Control&#148; of the Company after the Public Offering and approved by the Company&#146;s Board of Directors (with &#147;Change of Control&#148;
meaning the transfer of the Company&#146;s voting securities in one transaction or a series of related transactions to a person or group of affiliated persons if, after such transfer, such person or group of affiliated persons would hold more than
50% of the outstanding voting securities of the Company (or the surviving entity)), provided that in the event that such transaction is not completed, the shares of Common Stock held by the undersigned shall remain subject to the restrictions
contained in this Letter Agreement, and provided further that in the event any shares of Common Stock not transferred in the Change of Control shall remain subject to the restrictions contained in this Letter Agreement, [and] </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(I)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[the transfer of shares of Common Stock under a trading plan pursuant to Rule
<FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act (a &#147;Trading Plan&#148;) that is existing on the date hereof which has been provided to the Representatives or its legal counsel; provided, that, to the extent a public
announcement or filing under the Exchange Act, if any, is required of or voluntarily made by or on behalf of the undersigned or the Company regarding such transfer, such announcement or filing shall include a statement that such transfer is in
accordance with an established Trading Plan;]<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>provided</U>
that in the case of any transfer or distribution pursuant to clause (C), (D), (E), (F) or (G)&nbsp;each donee, transferee, heir, beneficiary or distributee shall execute and deliver to the Representatives a
<FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of this Letter Agreement; and <U>provided</U>, <U>further</U>, that in the case of any transfer or distribution pursuant to clause (B), (C), (D), (E), or (F), no filing by any party
(the undersigned, beneficiary, heir, donor, donee, transferor or transferee) under the Securities Exchange Act of 1934, as amended, (&#147;the Exchange Act&#148;) or other public announcement shall be required or shall be made voluntarily in
connection with such transfer or distribution (other than a filing on a Form 5 and any required Schedule 13F, 13G or 13G/A, in each case made after the expiration of the Restricted Period referred to above). </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">[NTD: To insert only for those individuals with trading plans in place.]
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the foregoing precludes the undersigned from
engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction
or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the undersigned or any other person) of any economic consequences of
ownership, in whole or in part, directly or indirectly, of any Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, whether any such transaction or arrangement (or instrument provided for thereunder) would
be settled by delivery of Common Stock or any securities convertible into or exercisable or exchangeable for Common Stock, in cash or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding anything to the contrary contained in this Letter Agreement, the undersigned may (i)&nbsp;exercise options or warrants to
purchase Common Stock of the Company pursuant to employee benefit plans or arrangements disclosed in the Prospectus (provided that (a)&nbsp;any Common Stock received upon such exercise or exchange will be subject to the restrictions provided for
under this Letter Agreement and (b)&nbsp;if the undersigned is required to file a report under Section&nbsp;16(a) of the Exchange Act during the Restricted Period, the undersigned shall clearly indicate in the footnotes thereto that such transfer is
pursuant to the circumstances described in this clause) and (ii)&nbsp;enter into any plan designed to satisfy the requirements of Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> (a <FONT STYLE="white-space:nowrap">&#147;10b5-1</FONT> Plan&#148;)
under the Exchange Act (other than the entry into such a plan in such a manner as to allow the sale of Common Stock within the Restricted Period); provided, however, that no sale of Common Stock may be made under such
<FONT STYLE="white-space:nowrap">10b5-1</FONT> Plan during the Restricted Period, and provided further that no filing by any party under the Exchange Act or other public announcement shall be made voluntarily in connection with establishment of such
plan and any required public disclosure of such plan (which the parties acknowledge is required by the Company under the Exchange Act) includes or refers to the restrictions set forth in this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For purposes of this Letter Agreement, (i) &#147;immediate family&#148; shall mean any relationship by blood, marriage or adoption, not more
remote than first cousin and (ii) &#147;change of control&#148; shall mean any bona fide third-party tender offer, merger, consolidation or other similar transaction, in each case, the result of which is that any &#147;person&#148; (as defined in
Section&nbsp;13(d)(3) of the Exchange Act), or group of persons, other than the Company, becomes the beneficial owner (as defined in Rules <FONT STYLE="white-space:nowrap">13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> of the
Exchange Act) of a majority of total voting power of the voting stock of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In furtherance of the foregoing, the Company, and
any duly appointed transfer agent for the registration or transfer of the securities described herein, are hereby authorized to decline to make any transfer of securities if such transfer would constitute a violation or breach of this Letter
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned hereby represents and warrants that the undersigned has full power and authority to enter into this Letter
Agreement. All authority herein conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal representatives of the undersigned. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges and agrees that the Underwriters have not provided any recommendation or investment advice nor have the
Underwriters solicited any action from the undersigned with respect to the Public Offering and the undersigned has consulted their own legal, accounting, financial, regulatory and tax advisors to the extent deemed appropriate. The undersigned
further </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
acknowledges and agrees that, although the Representatives may be required or choose to provide certain Regulation Best Interest and Form CRS disclosures to you in connection with the Public
Offering, the Representatives and the other Underwriters are not making a recommendation to you to enter into this Letter Agreement and nothing set forth in such disclosures is intended to suggest that the Representatives or any Underwriters is
making such a recommendation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The undersigned understands that (i)&nbsp;if the Underwriting Agreement does not become effective by
March&nbsp;31, 2024, (ii) if the Underwriting Agreement (other than the provisions thereof which survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder, (iii)&nbsp;if the
Representatives, on the one hand, or the Company, on the other hand, informs the other in writing, prior to the execution of the Underwriting Agreement, that it has determined not to proceed with the Public Offering, or (iv)&nbsp;prior to execution
of the Underwriting Agreement, if the Company files an application with the SEC to withdraw the registration statement related to the Public Offering, then the undersigned shall be released from, all obligations under this Letter Agreement. The
undersigned understands that the Underwriters are entering into the Underwriting Agreement and proceeding with the Public Offering in reliance upon this Letter Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Signature Page Follows</I>] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Letter Agreement and any claim, controversy or dispute arising under or related to this
Letter Agreement shall be governed by and construed in accordance with the laws of the State of New York, without regard to the conflict of laws principles thereof. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Security Holder <I>(Print exact name)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Signature</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">If not signing in an individual capacity:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name of Authorized Signatory <I>(Print)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title of Authorized Signatory <I>(Print)</I></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><I>(indicate capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</I></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d808358dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g808358g0306092642617.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter <SMALL>LLP</SMALL></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Northern
Avenue</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02210</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 617 570 1000</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">March&nbsp;6, 2024 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Akero Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">601 Gateway Blvd. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">South San Francisco, CA 94080 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Securities Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U>
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on
<FONT STYLE="white-space:nowrap">Form&nbsp;S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-256229)</FONT> (the &#147;Registration Statement&#148;) filed and deemed effective on May&nbsp;18, 2021 with the Securities and Exchange
Commission (the &#147;Commission&#148;) pursuant to the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), relating to the registration of the offer by Akero Therapeutics, Inc., a Delaware corporation (the &#147;Company&#148;), of
any combination of securities of the types specified therein. Reference is made to our opinion letter dated May&nbsp;18, 2021 and included as Exhibit&nbsp;5.1 to the Registration Statement. We are delivering this supplemental opinion letter in
connection with the prospectus supplement (the &#147;Prospectus Supplement&#148;) filed on March&nbsp;6, 2024 by the Company with the Commission pursuant to Rule&nbsp;424 under the Securities Act. The Prospectus Supplement relates to the offering by
the Company of up to 12,650,000 shares of the Company&#146;s common stock, par value $0.0001 per share (the &#147;Shares&#148;), covered by the Registration Statement. The Shares include an over-allotment option granted to the underwriters of the
offering to purchase 1,650,000 Shares. The Shares are being sold to the several underwriters named in, and pursuant to, an underwriting agreement among the Company and such underwriters (the &#147;Underwriting Agreement&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinion set forth below. We have relied, without
independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinion set forth below is limited to the Delaware General Corporation Law. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, when delivered and paid for in accordance with the terms of the
Underwriting Agreement, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter and the
opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 <I>Business Lawyer</I> 815 (Summer 2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
hereby consent to the inclusion of this opinion as Exhibit&nbsp;5.1 to the Registration Statement and to the references to our firm under the caption &#147;Legal Matters&#148; in the Registration Statement. In giving our consent, we do not admit
that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">/s/ Goodwin Procter LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">GOODWIN PROCTER <SMALL>LLP</SMALL></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>akro-20240305.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 3/7/2024 3:04:08 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:akro="http://www.akerotx.com/20240305"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.akerotx.com/20240305"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akro-20240305_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="akro-20240305_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>akro-20240305_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 3/7/2024 3:04:08 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>akro-20240305_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 3/7/2024 3:04:08 AM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="akro-20240305.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g808358g0306092642617.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g808358g0306092642617.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L ,<# 2(  A$! Q$!_\0
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M.NTC@_3K0!UE%5[V]MM/LY;N[G2"WB7<\CG 45YY<_&;2$N&2TTV^NHE/,H
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144 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.0.1</span><table class="report" border="0" cellspacing="2" id="idm140524415081040">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 05, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001744659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar.  05,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Akero Therapeutics, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38944<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-5266573<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">601 Gateway Boulevard<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">South San Francisco<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94080<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">487-6488<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AKRO<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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M#RP/9'I;K?%NXQ/R^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q
M_G@>F*FX3YI"5S%NV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"
MIQ%', ;  4/2='@//GL?)=-[*CG_5U/\!%!+ P04    "  ZBV98EXJ[',
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M9E@<.&7J/P$  #P"   /    >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y
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M%0:P;W(@"2[)E1M27>EYIK=WDWM)J'7N0;#W\!J-'<V/'[?\ 5!+ P04
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MUDX:?^:+X3]>?P%02P$"% ,4    "  ZBV98!T%-8H$   "Q    $
M        @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( #J+9E@7
M@SQ[[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM
M;%!+ 0(4 Q0    ( #J+9EB97)PC$ 8  )PG   3              "  <T!
M  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ .HMF6*W1+T%Q!
M0Q$  !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM
M;%!+ 0(4 Q0    ( #J+9EB?H!OPL0(  .(,   -              "  ;4,
M  !X;"]S='EL97,N>&UL4$L! A0#%     @ .HMF6)>*NQS     $P(   L
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64$L%!@     )  D /@(  !44      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d808358d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>akro-20240305.xsd</File>
    <File>akro-20240305_lab.xml</File>
    <File>akro-20240305_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d808358d8k.htm">d808358d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d808358d8k.htm": {
   "nsprefix": "akro",
   "nsuri": "http://www.akerotx.com/20240305",
   "dts": {
    "schema": {
     "local": [
      "akro-20240305.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "akro-20240305_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "akro-20240305_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d808358d8k.htm"
     ]
    }
   },
   "keyStandard": 23,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 24,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 23
   },
   "report": {
    "R1": {
     "role": "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-03-05_to_2024-03-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d808358d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-03-05_to_2024-03-05",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d808358d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.akerotx.com//20240305/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-24-060883-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-060883-xbrl.zip
M4$L#!!0    ( #J+9EAR,F>F/@,  $@+   1    86MR;RTR,#(T,#,P-2YX
M<V2]5DUOXS80O2^P_V&J4PM4HF1OVD:(LTB;#1 @FQ;>;-';@I;&#A&*5$DJ
ML?]]AY3DR$[L.DE17TQSYLV\^:1//BXK"?=HK-!J$F5)&@&J0I="+2918V-N
M"R&BCZ?OWYU\%\=P?G%Y#3'<.E?;G+&'AX>DG MEM6P<6;!)H2L&<=SK_W;S
M%?YLK><P18G<(E3<.C3P:R-DF8_2T3A+LU$R&L(,<F\/2NXPAS'[F9'>!QCG
MZ8<\_07./L.G8$3!C:APB-3URHC%K8/OBQ\@@,ZU4B@EKN!"**X*P25\Z0G_
M")>J2.!,2IAZF"66%LT]EDEG=6G+W!:W6/'W[P H7<KFBDPVU23R>>C2L)P9
MF6BS8*4SS*UJ9*04DQ8:440#Z+_CGF"H#EYBU\ YM[, ZB4^/>,!@M\9O>&&
MWZ'1;AGJX[.2CM.C@7Z)8JT>&%DLDH6^9R38MNWEXOD81FDZ9M0.CM*, X@4
MZFX/PHMGU!E#)T\@#^, R(Z/CUF0;E$JW68$G?4CU@J#-G?.B%GC\$*;ZASG
MO)&$:M3?#9=B+K ,6M2F%2JWH;.IX;A9H+OF%=J:%_B23%,[/1<6,<W87Y^O
MOH1.BTX] " TGZAJ;1RT/7BEBS 9>[+I?\5]$6)_%6>C>)PE9"P"]2SI'14$
M]F8B?6U?163=& <3L;L:V!]B?]CE_?FV?W4&ML?9QW_LX\]^.BC^)^O@/V"B
MU?5;R0QVVNMKHK@HVI75'@^ORR/R3;W9+P6?AZ.]CK>W2.<U^.1*:1<<#9GP
MNA9JKKLKNO1-G/>=/,4YA.V5<U,8+7'_CF.UT34:)VC%/PY#:^#6X'P2^4T?
M]WOFF^2SA/9,K_+$P>9X>3$C",JK1WH]U@GGP5=>#%Y.;R67:].^'2:1I;S+
MP7C^S^'6!E\:+D$L+?=0MMU1_S'0>G'PWL\-:8 _?)U>[GP>UN\#<WRIE:Y6
M+<=S733^!>J_SU3Y21&SU24UEJD"JP@$/2134O]VD/J:8\^R1/KC)D+W9JG_
MT/^ZWL+PR%4)K3D8V#MAVT:V[3<6R]_5:3@77!:-7.>\ W<:^X#;U3H<^<AL
M-ZZ[[>O53S';'N/N9CCN[56[;NCG/U!+ P04    "  ZBV985"(;9'H&  "X
M1@  %0   &%K<F\M,C R-# S,#5?;&%B+GAM;,V<;V_;-A#&WQ?H=[AY;S:@
MLF.[P!:C:9$Y21$L;8+$W88-0R%+C$U,)@U2CNUO/U)_&CFF9"H\57G15I'N
MGKM'^9W*2'+>?=@L(G@@0E+.3CK][E$'" MX2-GLI+.2GB\#2CL@8Y^%?L09
M.>ELB>Q\>/_ZU;L?/ _.+BX_@P?S.%[*4:^W7J^[X3UEDD>K6$G*;L 7/?"\
M/'X\^0)_I.5&<$LBXDL""U_&1,!O*QJ%H\'18-@_Z@^Z@V*:(+[6@]"/R0B&
MO5]Z*NXM#$=';T='O\+I)SA/1!A,Z((4,_ER*^AL'L-/P<^0))UQQD@4D2U<
M4.:S@/H1W.4-OX%+%G3A-(K@5J=)U:4DXH&$W4PUHNR_D?YKJGN'UZ\ U$ED
M,MEWTM&G(CL3FZF(NES,5*]'PUZ>TGG,V.REK(=)0O_X^+B7'"U&2VJ*5>+]
MWE^?KNZ".5GXGCKYZIL59&4D'<ED_Q4/DC-HT2"41NBOO#S,T[N\_L ;]KL;
M&7;>ZX+9V?&G)+I26Y!X& D>D8K"^G!2O9/%Q]NEBB>;F+"09,K?M'F01<T%
MN4]5-7J)I"1!=\8?>B&A&I"AWO#TAN[P1_7%US%7M)].92S\(-ZM%^E3Q$6^
M,S%QTC$D]78;TG&G(MC1\D60ZZC- _ZSB%[ U?=M&7N)8IY^+_C"V$56CAL.
M?HVFD;%-39+:TL--F/?E[I#75*AH3!#)5T+A5>=;F_AYGRC#/[GVO^]ZC[5?
M2JOJ$B+)5=U^W9 \72C,U9_X(O)GMD@^26H)27/KW'#0!4F#$!*2WY1!2SL#
MV4"C12!MNW7#\9S%--Z.51GA1Y?J KSYG6QML2Q);@G/:BN\(L@%UPI!)&S3
M"I"5@*0&J"+. #?8>A'D^OV[(7W&@Y6>FXGJWI;DW9R6 #8VSO>/N>"ZKX-$
M:2X,6MD93?PVBT1:]HJ#X0T1E(?G+#Q3/\W4Y?%)<LM@FJWPBB ,5 V"V,RF
M)4#5 %T$#=\&6C=R;-T_QF+AELRH7B2S^+._L";:G-OJ4J'$""^/<5\HF/1P
MUPF/%4"70%HE--&W89%@W3P&R)<LX&+)17*KY"Y6@S/F*[5(V8YY6)/K U*M
M8FYGDUNGN ^!A3SN3.P4A*0B9"5!UT0:DN_@RS SSS>',407-"*?5XLI$?4F
MIIC7ZG@8#'#S<7?PGVKA4J[5(95' AJ[7P.]5DUC@#KQ-Y>A6BS1>YK>''\.
MM:4BK2)\R!JW"':'NU(8EW15"G9KX7+?J!7#$#S##\9(G(:A,B"S?ZXH(_UZ
MXV 4:'44JBSQ X'N(U JBHM_IO\FWP!=":X9UCJF,1L&])_AI1GT!Z[H#UX<
M^@-;] =-H#_X?NA/UKPQ])%L6*-?Z041_;':O!83OF;/ K^8_A*P-]@Q0?\8
MAH;\4\F&@-=E@ O0A7!AQS90A;J="T3,DY^'K\6-X ^4!35OZY1IO 3@RXR9
MJ'\2BX:^4;<A_M,;&PJ=O!KN$#1BI6H2:OA!'(<;+F,_^ILNZ]_C-"N\A%$P
MFS(-PDXDVA@85!L:@K02J%*8]RV;LU$U -9>'-\!U 8%\>L OYO3UAN IL;Y
M_C&G]__V=)# 3?Z?U\HXG.+WN?/NGV6S;B#JEW*CFSEG->^7[^>U!&2I 6X^
M[@*F60L)SD0<$G6L^X;-]%N$M$[3;J#^*6@<$S;FB\6*9?<CI2VM)<DM(5MM
MA5<$N<!;(8A$<%8!=DLX4]Q@XT64ZW;OAO,=CVA 8\IFG]2*6U _LF79E-D2
MR!4F>%F$"\)E:DC\/LI#KN\,;U,M%\FMU;<;MC>"Z/D@"HOD34C]Z1AQ?7]O
MOW"H4F@)8PM3_%"D"]:'5)'P5F6@6 ?20I!4<@:]:1-%X)_I!!7]2RE71+@/
M@$'G98Q!N4'S,.S%(XY$B793@Y&6:W0^&G)4.26U;#DN;TBP4NNI;7\PG= X
MLK['L9_7UM*FS  W'W=:UABUL!8UF3@H=4CDW=<TC?2[LZ*IT;0;J!/AZT^:
MWVT74VZ]!'^2U!*BYM:YX: +G 8A)#(S94BEG:ELH-$BDK;=XEPWSS?!7+DE
M=3[,8,YM^?II-,++8S"NH_MZV-?2O +.AQF:Z]MX3;5L'N/YWOF"B)F:FH^"
MK^.Y6HPL?5;S@[PE$JT^X:NVQ0^&NC_CJY!%8CU[,)87@K029*60GO$U:,/P
MD,_62W''E=K2OW(EVT737SRB]OP/4$L#!!0    ( #J+9EB4G?1CP 0  #PL
M   5    86MR;RTR,#(T,#,P-5]P<F4N>&ULU9I=C^(V%(;O5]K_X*8WK=00
M/F:[.VB8%65F*M3Y$K!MU9N520Y@C6-'MAG@W_<XX)9 F(79;15SP8?C]_CU
M>1P3.[GXN$PY>0:EF12=H%&K!P1$+!,FIIU@KD.J8\8"H@T5">520"=8@0X^
M7KY]<_%=&)*KF_X]"<G,F$RWHVBQ6-22"1-:\KG!D+H6RS0B8>CJ]T:?R._K
MYMID !RH!I)2;4"17^:,)^UFO=EJU!O-6G-;IH#:>"2A!MJD%;V/L-X9:;7K
M9^WZ!]*](]=Y$$%&+(5MI<Q6BDUGAOP0_TART944 CB'%;EA@HJ844Z&SO!/
MI"_B&NER3@96IM&E!O4,26T3E3/QU+9O8^N=O'U#\(5I%#HO[00V&9M<+,>*
MUZ2:HMMZ*W*B8%NSW!,M6KFD<7Y^'N5'B_4U*ZN-#32B/^]NA_$,4AHB D06
M[S2%;A+SCWK;W+MH?=#5UZRM\TBW,LXS?T2WR,$:]E?HJH6V*&PTPU:CMM1)
M<&F;7&=520X#F!#[^6G0+[1)GT!)L\P'5 Z_WD+7ABZED.DJLI+H2L;S%(1Q
MGUV17 O#S*HO)E*E>4<"DN>T/5,PZ03T2<G01;-VOA]@H,^G!#*K#,\*S=*,
M0T"BK>YD"H>.,'GM6RPH"&!I0"20N#"V _]-AR_73#<#5\:%!+@S-P>F(:Y-
MY7.4 +,MMNP7FYU6GAG\\;DG<;+HCK51-#;%#' [4J1RA9R.@7>"$E'T+0UU
ML=N)[?H-I]-C#>V(BH:VJ7557 A)5>S"X=<]9,51OZD1951AO#">X?3FU!,E
MT]+D;%J3I4:E2D!U@F:SAF=[0#+%I$+86!*0N48O,K.N*;?'8 )*07*[[O9!
ME[E%G#DUY#6_,9[U:.QA#Q3E?1SOR]]@=2RF ^+JXCI@V&%K>8/-S2<C3..Q
MM(J:ZD(J^G1LWGG'YA'0*T[WR15>$YT*:4=<?5H[AAVVG[W!MIX;!C!EMJ/"
MW-/T:&KEVNI"*_?KF+WWC!DN"*3*I,I3.\0,0T_.<8I?]61R(L(OA*HZT2_8
M=X _> ;XAG&XGZ=C4*?1W-95'=VV5\?IW#-.([KL)Y@&-F'K1>EKH!T,4G6"
M!XUO<+;JGN'L)@DF66\^<($,C=-0E@:H.L92TPYAPWN$S:]%V/018?-?A+ZM
MS3>]Z.'7!S62"_$J@-MR3_!M6W;P_%FA%[J27XH]J$<EGYG=]'T-P;T8GF#<
M\^U8GOG)\E%J0_E?+#M]=5$>P1...ZX=17_V9>Q\TE5 3^%6U%275-&G8^//
MYHN]B\4?9U*<N,[;UU67T;Y7Q\F?#9<_T)\!T9-I.A>;98X^%M8!<76)'3#L
ML/FSC3*4G,7,,#&]PS]CQ:RUXYB5*:L+K,RMH^7/9LJC COD *^6\OL@]C:T
M>IA,CI\67XI077HON=Y0//-G#V6G-WVMYZ"^GF5)'&^(EGAW7/W96!E"/+<6
M&\WQB!E^]*7DOJZZW/:].D[^[)Z,%+5/R0U7Z5@>_7>W(ZHNH1VC#H\_^R-N
MB%TOXQD54SCE=FNYMKJPROTZ9K[M@URGH*8X]GY5<F%F.+]G5)SXR-"!$-4E
M^*)M!_)_V JYB/92<XL%]K'7]1'[9A_BQ)*_ 5!+ P04    "  ZBV98D37-
M'/T6  #\?@  #@   &0X,#@S-3AD.&LN:'1M[5WM4^.VUO_.7Z%);UN8R9OS
M B2PN4.SV5UN66 2.NU]OG046R$NCN5*-B3/7_^<(\F.[20DD "[3^E,-XDM
M2T?G]7>.)'/Z[^G$(_=,2)?['WZVRM6?"?-M[KC^[8>?SP;=\_.?_]W9.QV'
MT R:^K+M,/=#81R&0;M2F0Z%5Y;,+M_R^PK<J-2JM7K!-(QD*9P%3":M1U0.
MRUS<5N([F>8^]_UHDC1^>'@HJ^[Q 2<4%7RB HU*T(H)UXZ?FWJN?Y=Y[*&N
M'K):K59%W8V;+K1,!JA5J_4*WAY2R>+F]$[P3'-ZQP0/IV6;3Y#T1K5>;29D
M2'<9$="Q5?GCZ\7 'K,)+;F^#*EO)T-$H5A)4*L"=^.&KN2-FG7T"/6F1?+
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M/^B(2&W.0QW5W2RC:K'KJR@$K@)_L6,@0$E*IU\3ZBKWAU[I@8L[+3;#=QA
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MD.E93P\+:!JY@(-5(G@TY\'<X>^(>IE7#.&!9L'"&=I&\C[9A=PNESOA8:A
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M);VJU8,P[DCWD9LB)B?9.A)8E#H=A\4J5]H>=2=2'S:>GTG&(G. CZZ98!F
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MD=6\U2#ZM*+_!+?ZZ]R=_P-02P,$%     @ .HMF6'*4/E4)K0  .X(# !
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M,V[)B]'V$S7^6+*ZSV>Y1,(D-US7%1D)-,!%ZK/H.GMWF60"I(M&2(T!M\^
M)R^)2%]RH+=#H:B_>"Q6HTNQDO09S/]OEBFA+QTG.L!J1-8$K.8Z_C9)1KZF
MPVVWK,&[Y]J5YL+^=U;F&B&$>Y;.$U WI"W*%5.6LMIGG\*.7?B1^6%T637L
M;]KJ')^L#U![[(D1V$P#.$E70V:3K3),=:>5./P(:NQ"LJ><2K82WNU8^N<I
M-D<%2NM2&F-*,T\X!%#^.!KNS4;I>.[?(S2""H0-&5,2%$(!6K\UFE(QE7T4
M2:$I45R\'U(=IQ+C&:\(AKNLFC,JHIMA@2M.$OONQ5%>8B#,T;W33H./?,0
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MW4@ M\=?0&79OBI4FY]HQ!"D8255"TFGAU'7!S(@'UOE$!Q7Y$]I\C%'\5E
M+Q8([NC1%63%,!A+[LII>QTW5]\]CQ#\E!V !D0POO)<!R5$1X#?IIC<=GR!
M[/38Y5WAZ1KQ=.NNR&+TN0NV)I(GW,_.7;[]%3AH[(HF>'GZTEI!FZB(@ZX0
M&QYB9FT1B[$DUZHX=!J8&K.BF6D> ALGI/EVS1./L2I4-L"U=U-:! $(2U/\
M28/BO22Q#"?:4 X%&A_2+@!#JO/T;(5N.-99^[D&X;^:BBU?1((T9Y35 G-
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MKHNRH!%AS[>UG-FEG\Q6O%20%^PR -NT:(+4Z.LR%Y^T+.E; [G))B79$>E
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MH:F6W"&2K(;K),$PW$H7A*TSAP!7')\PT[8X;J:G'^$8W(I4=P:Q5.)T;TX
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M)&D_@6Q3LQGT-P%/=&"G0J0..'4CT];S4^Z-"T\X@M+AXA1R\ <H<*WP!RP
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M,S/#2&K YBD*8L!#DMQ@O+<[9C?H2N4-;WH42RBLI3/2J!A*DLSZ)&2B2C<
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M_(%6!V)U.1,;&-N-ZNX"ABH,O/$5-47E>]D8X46[S4,RM-?3!<V=_,!>R\O
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M\$'!8J$#RO70[(@^27=Z:[8[_?-/[[]^^!=\^,O)KY]W_C]02P,$%     @
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M%>%Q8FM7Z",E#NI/F_\%4$L! A0#%     @ .HMF6'(R9Z8^ P  2 L  !$
M             ( !     &%K<F\M,C R-# S,#4N>'-D4$L! A0#%     @
M.HMF6%0B&V1Z!@  N$8  !4              ( !;0,  &%K<F\M,C R-# S
M,#5?;&%B+GAM;%!+ 0(4 Q0    ( #J+9EB4G?1CP 0  #PL   5
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-  8 ?0$  /;;      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>d808358d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="akro-20240305.xsd" xlink:type="simple"/>
    <context id="duration_2024-03-05_to_2024-03-05">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001744659</identifier>
        </entity>
        <period>
            <startDate>2024-03-05</startDate>
            <endDate>2024-03-05</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-278">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-03-05_to_2024-03-05"
      id="Hidden_dei_EntityCentralIndexKey">0001744659</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-289">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-290">2024-03-05</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-291">Akero Therapeutics, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-292">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-293">001-38944</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-294">81-5266573</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-295">601 Gateway Boulevard</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-296">Suite 350</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-297">South San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-298">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-299">94080</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-300">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-301">487-6488</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-302">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-303">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-304">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-305">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-306">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-307">AKRO</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-308">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-03-05_to_2024-03-05" id="ixv-309">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
